site visit update division of therapeutic proteins n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Site Visit Update: Division of Therapeutic Proteins PowerPoint Presentation
Download Presentation
Site Visit Update: Division of Therapeutic Proteins

Loading in 2 Seconds...

play fullscreen
1 / 17

Site Visit Update: Division of Therapeutic Proteins - PowerPoint PPT Presentation


  • 720 Views
  • Uploaded on

Site Visit Update: Division of Therapeutic Proteins. Amy Rosenberg, MD, Director. Amy Rosenberg, MD, Director Barry Cherney, Ph.D, Deputy Director Sandra Chung, Secretary. Laboratory of Biochemistry Emily Shacter, Ph.D., Chief Jee Chung, Ph.D., IOTF Fellow Hiroshi Uehara, Ph.D., Biollgist.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Site Visit Update: Division of Therapeutic Proteins' - paul


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
the division of therapeutic proteins

Amy Rosenberg, MD, Director

Barry Cherney, Ph.D, Deputy Director

Sandra Chung, Secretary

Laboratory of Biochemistry

Emily Shacter, Ph.D., Chief

Jee Chung, Ph.D., IOTF Fellow

Hiroshi Uehara, Ph.D., Biollgist

Laboratory of Chemistry

Gibbes Johnson, Ph.D., Chief

Y-X Fan, Ph.D., Visiting Associate

N. Spiridinov, Ph.D., Visiting Associate

Lily Wong, Microbiologist

Laboratory of Immunology

Elizabeth Shores, Ph.D., Chief

Baolin Zhang, Ph.D., Senior Staff Fellow

Yaqin Zhang, MD

Serge Beaucage, Ph.D., PI

A Grajkowski, Ph.D., Visit Associate

J. Cieslak, Ph.D., Visit Associate

Michael Norcross, MD PI

Jinhai Wang,MD Staff Scientist

Gregory Rodriquez, Microbiologist

Akhilesh Nagaich, Ph.D., Senior Staff Fellow

Amy Rosenberg, MD PI

Hugh McFarland, Ph.D, Staff Scientist

Lai Xu, Ph.D., MD, Staff Fellow

Karen Mason, Bio Lab Tech

Full Time Review Staff

Ingrid Markovic, Ph.D.

Dov Pluznik, Ph.D..

Kathy Lee, MS

Full Time Review Staff.

Wei Guo, Ph.D.

Kurt Stromberg, MD

Emmanuela Lacana, Ph.D.

  • Edward Max, Ph.D., MD PI
  • Frederick Mills, Ph.D., Staff Scientist
  • Aruchandran, Ph.D. Microbiologist
  • Ralph Bernstein, Ph.D.

Daniela Verthelyi, Ph.D., MD.

Senior Staff Fellow

J. Pedras-Vasconcelos, Visiting Associate

M. Puig, Visiting Associate

Vivian Wang, Microbiologist

Raymond Donnelly, Ph.D., PI

H. Dickensheets, Ph.D., Staff Scientist

Faruk Sheikh, Ph.D. Visiting Associate

Full Time Review Staff

Susan Kirshner, Ph.D

Ennan Guan, Ph.D., MD

.

The Division of Therapeutic Proteins
laboratory of immunology regulatory responsibilities
Laboratory of Immunology: Regulatory Responsibilities
  • Expert regulation of numerous products whose activity or origin is immune system based
  • Expert regulation of products regulated in other laboratories
  • Immunogenicity assessments on all licensed

and IND products in DTP

  • Consultation to other FDA Centers regarding immunogenicity
  • Immunogenicity Guidance Documents: clinical concerns and assay guidance
  • Immunocomparability Guidance for follow-on proteins
laboratory of immunology regulatory responsibilities products
Laboratory of Immunology: Regulatory Responsibilities - Products
  • Immunomodulators
  • Immunogenicity Assessments: all DTP products
    • (Wang, Bernstein, Mills, Norcross)
    • for autoimmune disease
      • (Mills, Bernstein, Norcross, Wang)
    • Innate immune system modulators
      • (Wang, Norcross)
  • Cytokines and Chemokines:
    • Interferons
      • (Bernstein, Wang, Norcross, Beaucage)
    • Interleukins

(Norcross)

Chemokines

(Norcross)

research program of michael norcross md
Reseach Program

Chemokine Biology

HIV-1 Immunopathogenesis

Cancer Biology

Immunology and Autoimmunity

Regulatory Program

Regulation of chemokine products: potency assays, mechanism of action

Regulation of protein therapeutics for HIV-1 treatment and prevention

Cytokines and interferons for treatment and immune reconstitution

Vaccine adjuvants

Chemokine receptor inhibitors

Regulation of protein therapeutics for treatment of malignant states

Evaluation of immunogenicity of therapeutic protein products; TNF inhibitor products

Research Program of Michael Norcross, MD
michael norcross m d accomplishments since site visit

Michael Norcross, M.D. Accomplishments Since Site Visit

Chemokines and Chemokine Receptors in HIV-1 infection and Immunology:

Heterodimeric interactions between different types of chemokines and receptors have been studied. Expression vectors are being generated to dissect the interactions between CCR5, CXCR4, CD4 and CD26 using FRET techniques. Physical interactions between these cell surface proteins may control susceptibility to infection and sensitivity to receptor ligands and antagonists.

Wang, J, Guan, E, and Norcross, MA. Heterodimer formation between CC and CXC chemokines (Manuscript in preparation)

Immune modulation and HIV-1 pathogenesis:

Studies are ongoing to examine the effects of HIV infection and HIV proteins on macrophage and dendritic cell function. HIV infection was found to induce partial dendritic cell activation that may contribute to chronic immune activation seen in HIV infected patients. Specific inhibitors of TLR receptors and scavenger receptors are being evaluated for effects on HIV mediated activation of monocytes and dendritic cells.

jinhai wang md promotion action
JinHai Wang, MD: Promotion Action
  • Research focus: chemokine receptors as host factors in HIV-1 infection and cancer biology
    • 6 first author publications since 2001
    • 1 patent filed
  • Non-CpG Immune Modulators
    • 1 publication
    • 1 patent filed
  • CMC Review Work: INDs and BLAs for HIV-1, HCV, cancer. Immunogenicity reviews for therapeutic enzymes
scientific accomplishments during mar 2007 jul 2007 jinhai wang m d
Scientific Accomplishments during Mar. 2007-Jul. 2007Jinhai Wang, M.D.

Presentation

  • Jinhai Wang. Immune Suppression and Regulatory Oligodeoxynucleotides. CDER, DTP seminar series, June 8, 2007

Patent application

  • Jinhai Wang, Michael Norcross, and Gregory Roderiquez (FDA). Inhibiting immune response by regulatory orthophosphorothioate non-CpG oligodeoxynucleotides. U.S. Provisional Patent Application, filed July, 2006. International PCT application to be filed July, 2007.

Publications

  • Jinhai Wang, Gregory Roderiquez, Taneishia Jones, Peter McPhie, and Michael A. Norcross. Control of In Vitro Immune Responses by Regulatory Oligodeoxynucleotides through Inhibition of pIII Promoter Directed Expression of MHC Class II Transactivator in Human Primary Monocytes. J Immunol 2007Jul 1,179, 45-52
  • Jinhai Wang, Jay Lozier, Gibbes Johnson, Susan Kirshner, Daniela Verthelyi, Anne Pariser, Elizabeth Shores, and Amy Rosenberg.Neutralizing Antibodies to Therapeutic Enzymes: Prediction, Prevention, and Treatment (Review). (Submitted to Nature Biotechnology).
  • Jinhai Wang.Dimerization of chemokine receptors in living cells: key to receptor functions and novel targets for cancer therapy (Review). (Under internal review)

Projects on going

  • Immune regulatory ODNs:

------Receptor, trafficking, and regulation of monocyte functions by pDCs.

Rhodamine-labeled rODNs were taken up by monocytes within minutes w/o pDC (Confocal). Labeled rODN entry into monocytes was not inhibited by anti-CXCL16 (Confocal & FACS). rODN was colocalized with lysosome marker within one hour (Confocal). rODNs induced FSC and SSC changes and prolonged the survival of monocytes significantly.

  • Chemokine receptors and cancer biology

------CXCR4, cancer factor, migration, and function of immune cells: a soluble factor secreted by breast cancer cells upregulated HLA-DR, downmodulated CXCR4on monocytes, blocked by anti-GM-CSF.

research program of edward max ph d md
Research Program

Class switch recombination

IgH Insulators: prediction, prevention, control of immune responses

Regulatory Program

Immunogenicity of protein therapeutics review

Immunomodulatory product review

products to activate B cells in setting of immune deficiency

product qualities associated with Tind and Tdep B cell activation, ie aggregates

Evaluation of biotech applications using insulators to stabilize and enhance transgene expression; replacement of defective genes, prevention of oncogene activation.

Research Program of Edward Max, Ph.D., MD
update dr max s group

Update: Dr. Max’s group

Class Switch Recombination project (Arudchandran, Bernstein):

Additional experiments completed to compare double- and single-strand DNA breaks in Ig Switch regions; only double stranded breaks are AID-dependent.

Manuscript submitted to J Exp. Med. “Single-strand DNA breaks in immunoglobulin Class Switch Recombination that depend on UNG but not AID”

ChIP experiments to assess APOBEC3 binding to Ig Switch regions; RTPCR for APOBEC3 expression in B cells

IgH Insulator project (Bernstein, Mills):

In vitro binding of candidate regulatory proteins USF1 and DB1 to insulator DNA has been characterized

Barrier activity flanking insulator further mapped

Manuscript draft: “A chromatin boundary element downstream of the human immunoglobulin heavy chain locus.”

ralph bernstein ph d conversion to staff scientist
Ralph Bernstein, Ph.D., Conversion to Staff Scientist
  • Research focus: Insulator elements 3’ of the Murine 3’ IgH LCR.
    • 3 papers since 2001
    • 3 manuscripts in preparation
  • CMC work:
    • primary reviewer of multiple therapeutic INDs;
    • on 4 committees for recently licensed DTP BLAs;
    • consult reviewer for CDRH and CDER licensed and IND protein products (not regulated by DTP)
  • Workshop presentations at multiple joint FDA/Industry meetings.
    • Co Moderator at 3 consecutive WCBP meetings
      • Techniques used to characterize tertiary structure: Tool Time for Tertiary Structure 2005
      • Comparability: Same Pieces + Same Blueprint = Same Product. 2006.
      • Challenges associated with the Development of Product Specific Assays for Cleaning validation. 2007.
    • Presentations:
      • Expectations & Case Reports for Biological Product Quality, at the Biological Therapeutic Products Workshop. April-06
      • Core Team Biologics TrainingOctober 21, 2004, ELISA and PCR assays
  • Multiple presentations of scientific and regulatory topics for FDA staff
ralph bernstein ph d conversion to staff scientist1
Ralph Bernstein, Ph.D., Conversion to Staff Scientist
  • Inspection Coordinationfor DTP Products:
    • coordination of biennial inspections (with OC);
    • identification of issues for inspection and briefing of inspectors,
    • advice for field inspectors on scientific issues;
    • performance of multiple inspections
  • IT Coordinator for DTP
    • Approval of computer hard and software for regulators and researchers
    • Email and data base access for reviewers
slide13

Update: Ralph Bernstein

IgH Insulator project:

  • Long-lasting barrier activity localized to a 0.5 kb DNA segment upstream of insulator
  • Study of DNase I hypersensitivity site upstream of murine insulator
  • Identification of insulator DNA fragments binding to DB1 and MAR-binding protein SATB2.
  • Preparation of a library of DNA fragments for an enhancer-blocking trap screen
  • Characterization of DNA methylation status of CpG sites in murine insulator
  • Critical contributions to two manuscripts
laboratory of chemistry regulatory responsibilities products
Laboratory of Chemistry: Regulatory Responsibilities - Products
  • Therapeutic Enzymes
    • Oncology Indications
      • (Beaucage)
    • Enzyme Replacement Therapies.
      • (Mills, Beaucage, Wang, Max)
    • Infectious Disease
      • (Norcross)
    • Counter Terrorism Enzyme
      • (Norcross)
    • Cystic Fibrosis
    • Pancreatic Insufficiency
serge beaucage ph d progress update
Research Program

Optimization of methods for production of diagnostic and therapeutic oligonucleotides

Expertise in Chemistry

Regulatory Program

Co-author Oligonucleotide guidance document;

Review of therapeutic oligonucleotides, siRNA INDs

Review of BLA-PCR Based Diagnostic (CBER)

Regulation of pegylated products: reaction kinetics, stability

Regulation of therapeutic enzymes: enzyme activity, stability.

Serge Beaucage, Ph.D., Progress Update
scientific accomplishments of serge l beaucage since the site visit

Scientific Accomplishments of Serge L. Beaucage Since the Site Visit

Publications:

1. Grajkowski, A., Cieślak, J., and Beaucage, S. L. Functionalization of Long Chain Alkylamine Controlled-Pore Glass for Thermolytic Release of DNA Oligonucleotides and Their Conjugates. To besubmitted for publication in Bioconjugate Chemistry.

2. Ausín, C. and Beaucage, S. L. Synthesis of Deoxyribonucleoside Phosphoramidites Functionalized with Lipophilic and Hydrophobic Groups at P(III) for Incorporation into CpG-Oligonucleotide Produgs. To besubmitted for publication in the Journal of Organic Chemistry.

3. Cieślak, J., Grajkowski, A., and Beaucage, S. L. The 4-(N-dichloroacetyl-N-methylaminobenzyloxy)methyl group for 2’-Hydroxyl protection in the Solid-Phase Synthesis of Oligoribonucleotides. To besubmitted for publication in the Journal of Organic Chemistry.

4. Beaucage, S. L. Solid-Phase Synthesis of siRNA Oligonucleotides. To besubmitted for publication in Current Opinion in Drug Discovery & Development.

scientific accomplishments of serge l beaucage since the site visit1
Scientific Accomplishments of Serge L. Beaucage Since the Site Visit
  • Invited Presentations at Symposia:
  • Assessment of Novel Phosphate/Thiophosphate Thermosensitive Protecting Groups in the Design of Thermolytic Oligonucleotide Prodrugs. EuroTIDES, Hotel Palace Berlin, Berlin, Germany, December 4-5, 2007.
  • Progress in the Synthesis of Thermolytic DNA Oligonucleotide Prodrugs and Oligoribonucleotides for Potential Therapeutic Applications. 41st IUPAC and CHEM-BIOTECH 2007 Congress in the Synthesis of Natural Products, Torino, Italy, August 5-11, 2007.
  • 4-Nitrogenated Benzyloxymethyl Groups for 2’-Hydroxyl Protection in the Solid-Phase Synthesis of siRNA Oligonucleotides. TIDES 2007 Oligonucleotides and Peptides Technology and Product Development, Red Rock Casino, Resort and Spa, Las Vegas, Nevada, May 20-23, 2007.
  • Thermosensitive Phosphate/thiophosphate Protecting Groups and the Development of Thermolytic Olifonucleotide Prodrugs. 17th International Conference on Phosphorus Chemistry, Xiamen, China, April 15-19, 2007.